BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively...
BC Extra | May 9, 2019
Company News

bluebird to rollout Zynteglo starting in Germany next half

bluebird expects to launch β-thalassemia gene therapy Zynteglo in Germany next half, followed by launches in Italy, France and the U.K. in 2020. In March, EMA's CHMP recommended conditional approval of Zynteglo to treat transfusion-dependent...
BC Extra | Apr 4, 2019
Company News

Cytovant launches with Asia focus, Medigene deal

Roivant and its Sinovant affiliate launched Cytovant, a new company that will seek to develop treatments for diseases prevalent in Asia. The newco also obtained a license in Asian territories to four T cell immunotherapy...
BC Extra | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
BC Extra | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
BC Week In Review | Jan 11, 2019
Company News

Medigene licenses co-stimulator from Helmholtz to overcome checkpoint blockade with TCRs

Medigene AG (Xetra:MDG1) received exclusive, worldwide rights to a chimeric co-stimulatory receptor from Helmholtz Zentrum München (Neuherberg, Germany) for therapeutic and diagnostic use in TCR therapies and DC vaccines. Helmholtz designed the co-stimulator, a fusion...
BC Innovations | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BC Extra | Aug 31, 2018
Company News

Management tracks: Medigene, Merck KGaA

Medigene AG (Xetra:MDG1) said CFO Thomas Taapken has resigned. Medigene is seeking a successor. Taapken, who joined the cancer immunotherapy company in January 2017, will continue to advise Medigene as a consultant through the end...
BC Week In Review | Aug 10, 2018
Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
BC Extra | Aug 6, 2018
Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
Items per page:
1 - 10 of 552
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively...
BC Extra | May 9, 2019
Company News

bluebird to rollout Zynteglo starting in Germany next half

bluebird expects to launch β-thalassemia gene therapy Zynteglo in Germany next half, followed by launches in Italy, France and the U.K. in 2020. In March, EMA's CHMP recommended conditional approval of Zynteglo to treat transfusion-dependent...
BC Extra | Apr 4, 2019
Company News

Cytovant launches with Asia focus, Medigene deal

Roivant and its Sinovant affiliate launched Cytovant, a new company that will seek to develop treatments for diseases prevalent in Asia. The newco also obtained a license in Asian territories to four T cell immunotherapy...
BC Extra | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
BC Extra | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
BC Week In Review | Jan 11, 2019
Company News

Medigene licenses co-stimulator from Helmholtz to overcome checkpoint blockade with TCRs

Medigene AG (Xetra:MDG1) received exclusive, worldwide rights to a chimeric co-stimulatory receptor from Helmholtz Zentrum München (Neuherberg, Germany) for therapeutic and diagnostic use in TCR therapies and DC vaccines. Helmholtz designed the co-stimulator, a fusion...
BC Innovations | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BC Extra | Aug 31, 2018
Company News

Management tracks: Medigene, Merck KGaA

Medigene AG (Xetra:MDG1) said CFO Thomas Taapken has resigned. Medigene is seeking a successor. Taapken, who joined the cancer immunotherapy company in January 2017, will continue to advise Medigene as a consultant through the end...
BC Week In Review | Aug 10, 2018
Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
BC Extra | Aug 6, 2018
Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
Items per page:
1 - 10 of 552